AstraZeneca (Sweden)

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

Dapagliflozin in Patients with Chronic Kidney Disease

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50...

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes

<i>De Novo</i> Determination of the Crystal Structure of a Large Drug Molecule by Crystal Structure Prediction-Based Powder NMR Crystallography

The crystal structure of form 4 of the drug 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid is determined using a protocol for NMR powder crystallography at n...